

Poly Medicare Limited

Regd Office: 232 B, 3rd Floor, Okhla Industrial Estate,
Phase-III, New Delhi - 110 020 (INDIA)
T +91-11- 33550700, 47317000
E: info@polymedicure.com W: polymedicure.com
CIN L 40300DL1995PLC066923



Date : 19th August, 2024

To,

The General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Fort
Mumbai 400 001

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (East)
Mumbai 400 051

BSE Scrip Code: 531768

NSE Symbol: POLYMED

Sub: Qualified institutions placement of equity shares of face value ₹ 5 each (the "Equity Shares") by Poly Medicare Limited (the "Company") under the provisions of Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the "SEBI ICDR Regulations"), and Sections 42 and 62(1)(c) of the Companies Act, 2013, as amended, including the rules made thereunder (the "Issue").

Dear Madam/ Sir,

- We wish to inform you that pursuant to the approval accorded by the board of directors of the Company (the "**Board**"), at its meeting held on 29th June, 2024 and special resolution passed by the members of the Company by way of postal ballot on 05th August, 2024, the QIP Committee has, at its meeting held today, *i.e.*, 19th August, 2024 *inter-alia*, considered and approved the following:
 - approval and adoption of the preliminary placement document dated 19th August, 2024 together with the application form dated 19th August, 2024 in connection with the Issue; and
 - approval and authorisation of the opening of the Issue today, *i.e.*, 19th August, 2024.
- We further wish to inform you that the QIP Committee has fixed the 'Relevant Date' for the purpose of the Issue, in terms of Regulation 171 of the SEBI ICDR Regulations, as **19th August, 2024** and accordingly the floor price in respect of the aforesaid Issue based on the pricing formula as prescribed under Regulation 176(1) of the SEBI ICDR Regulations is **₹ 1880.6875** per Equity Share. Pursuant to Regulation 176(1) of the SEBI ICDR Regulations, the Company may at its discretion offer a discount of not more than 5% on the floor price so calculated for the Issue. The Issue Price will be determined by the Company in consultation with the book running lead managers appointed in relation to the Issue.

Copy of the same is being also made available on the website of the Company at www.polymedicure.com.

A certified copy of the resolution passed by the QIP Committee authorising the opening of the Issue and fixing the Floor Price and Relevant Date is enclosed for your information and records.

In relation to the Issue, we will file the Preliminary Placement Document with BSE Limited and National Stock Exchange of India Limited on 19th August, 2024.

The meeting of the QIP Committee commenced at 16.30 p.m. and concluded at 05:15 p.m.

Further, as per Company's Prevention of Insider Trading Code of Conduct to regulate, monitor and report trading by Designated Persons ("**Code**"), the trading window for dealing in the securities of the Company will be closed from the intimation of Outcome of this Meeting, till 48 hours after Listing of shares at Stock Exchanges.

We request you to take the above on record and treat the same as compliance under the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Thanking you,

For Poly Medicure Limited


Avinash Chandra
Company Secretary

